New drug cocktail aims to wipe out hard-to-treat stomach cancer before surgery

NCT ID NCT04656041

Recruiting now Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a new drug (liposomal irinotecan) to standard chemotherapy before chemoradiation can completely eliminate cancer in people with advanced gastroesophageal cancer. About 40 adults with stage T3/4 or node-positive disease will receive the combination, then surgery. The main goal is to see how many have no cancer cells left in the removed tissue. Side effects will also be tracked.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGOGASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGOGASTRIC CANCER GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

Beth-Israel Deaconess Medical Center
NOT_YET_RECRUITING

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital at Newton Wellesley Hospital
RECRUITING

Newton, Massachusetts, 02462, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.